Compare
Innoviva vs Merck & (INVA vs MRK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Innoviva (INVA) returned +4.8% and Merck & (MRK) +73.9%; so far this year the figures are -4.5% and +39.4%.
Merck & is the larger company by market value, about 266.0 times the size of Innoviva.
On trailing earnings, INVA trades at 9.6 times and MRK at 149.7 times.
Revenue grew +12.8% at INVA and +4.9% at MRK over the last year.
INVA pays no dividend. MRK yields 2.32%.
Data as of the latest close. Not investment advice.
Relative performance
| INVA | MRK | |
|---|---|---|
| Price | $19.10 | $146.73 |
| 1-day | -0.73% | -0.14% |
| YTD | -4.45% | +39.40% |
| 1 year | +4.77% | +73.87% |
| 3 years | +53.78% | +42.66% |
| Market cap | $1.4B | $361.7B |
| P/E | 9.6 | 149.7 |
| P/S | 3.10 | 5.37 |
| P/B | 1.19 | 8.06 |
| Revenue growth | +12.80% | +4.90% |
| EPS growth | +40.80% | -87.10% |
| Gross margin % | 74.5 | 71.8 |
| Net margin % | 44.1 | 3.6 |
| ROE % | 17.0 | 5.5 |
| Debt / equity | 0.23 | 1.20 |
| FCF yield % | 13.4 | 4.1 |
| Dividend yield % | — | 2.32 |
| Beta | 0.28 | 0.18 |
| RSI (14) | 31.2 | 51.3 |
| Technical rating |